GLSI
Greenwich LifeSciences, Inc.
$16.03
+3.55%
2026-10-23
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
Key Fundamentals
Forward P/E
-22.22
EPS (TTM)
$-1.59
ROE
-986.3%
Profit Margin
0.0%
Price/Book
85.94
Beta
1.46
Market Cap
$267.4M
Avg Volume (10D)
145K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$20.31
60D Low
$13.18
Avg Volume
125K
Latest Close
$16.03
Get breakout alerts for GLSI
Sign up for Breakout Scanner to receive daily notifications when GLSI triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Greenwich LifeSciences, Inc. (GLSI) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors GLSI daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. GLSI operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.